🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Diwali2024

Quitting smoking after a cancer diagnosis significantly increases survival, regardless of cancer type The sooner you quit, the better: Those who quit within 3 months of diagnosis had a 25% lower risk of death, 6 months = 21% lower, and 9 months = 15% lower. 75th percentile

An important work to understand AML at relapse by Alex Bataller

Meeting my friend Jayastu Senapati at #ASH24 Thankful to his and Gautam Borthakur Hagop Kantarjian,MD mentorship for FLAG-GO vs FLAG-IDA outcomes study!

It’s always a pleasure to meet dear friend Julie Braish and mentors Naveen Pemmaraju, MD G Garcia-Manero Nitin Jain #ASH24 Many congrats to Julie Braish for match at Moffitt Hematology/Oncology Fellowship

Dr. Tapan Kadia is presenting results of a phase II trial at #ASH24 of venetoclax in combination with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukemia and high-risk MDS. Read more: bit.ly/3DgyXwy Tapan Kadia #EndCancer

Proud mentor of Mehndi Dandwani presenting our #MGRS data at #ASH24 as poster tonight. -> Hematological ≥VGPR to induction significantly affecting TTNT (HR 0.07, p<0.001) on univariate and multivariate. -> Novel therapies, including anti-CD38 had + outcomes, results not SS.

CONGRESS | #ASH24 | PRESENTATION Tapan M. Kadia Tapan Kadia MD Anderson Cancer Center presents a subgroup analysis of a phase II trial of venetoclax combined with intensive chemotherapy in patients with ND AML. Pegfilgrastim use improved the time to count recovery and decreased the incidence

Epcoritamab monotherapy as 1L in anthracycline-inelegible pts with newly LBCL: - Me age 81 yo (77-95), IPI 3-5 58%, frequent CV commorbidities - ORR 69%/CR 62%. Me time to response/CR 1.5/2.5 mo - 6mo PFS/OS 73%/81% - CRS 71% (G3 5%, most C1 D15). ICANS 16% #ASH24 #lymphoma

In a study of combined Pirtobrutinib, Venetoclax and Obinutuzumab as a first-line treatment for patients with chronic lymphocytic leukemia (CLL) with a median follow up of nearly a year, no patients have progressed or died, our Nitin Jain reported. Read more:

Lung Cancer Wrapped > Spotify Wrapped Here’s your 2024 Year in Review of FDA Oncology approvals in lung cancer! U.S. FDA OncoAlert Oncology Brothers #lcsm

➡️ Check out our paper on Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms Haematologica haematologica.org/haematologica/… ✅ A clinically relevant and easy to use TP53 aberration burden stratification and a closer look at outcomes

Just out! Fantastic paper by Naseema Gangat and colleagues: Mayo Clinic Genetic Risk models in Venetoclax-HMA treated Acute Myeloid Leukemia. AML #AyalewTefferi Tapan Kadia Mrinal Patnaik Aref Al-Kali nam12.safelinks.protection.outlook.com/?url=https%3A%…

As we have increasing Rx options in Firstline #CLL including new updates from #ASH24, here is a summary slide I made for PFS in selected trials by IGHV status caveat: cross trial comparison but still helpful as we look across trials #CLL #leusm MD Anderson Cancer Center ASH

Merry Christmas and Happy New Year! UI Holden Comprehensive Cancer Center University of Iowa

🚨 ICAHT & CAR-HEMATOTOX Score in CAR-T Therapy: Comprehensive Review & Practical Insights 🚨 🩸 Immune Effector Cell-Associated Hematotoxicity (ICAHT) = Prolonged cytopenias post-CAR-T 🛑 CAR-HEMATOTOX Score = Predicting risk of severe hematologic toxicity 📉 Both impact

Honored to have Dr. Aparna Parikh Aparna Raj Parikh Mass General Cancer Center in Iowa City for the C Patrick Burns Lecture on “ctDNA in colorectal cancer”. Couldn’t have asked for a better speaker for discussion on this hot topic. Eagerly looking forward to the lecture tomorrow. UI Holden Comprehensive Cancer Center

🙏🙂 Very happy to share our manuscript on a granular analysis of a large cohort of Secondary Type AML with respect to contemporary therapies: ➡️ Clinico-genomic classification of AML ontogeny: Clinical secondary (CS), Genomic Secondary (GS) and Pure De novo (DN) AML🧬 ➡️ GS-AML

Updated results of our frontline trial of FLAG-IDA+VEN, showing CRc in 95% of newly diagnosed #AML. Responses were seen across all ELN22 risk groups, w/ 90% MRD neg. In RR AML, 79% first salvage & TP53wt attained CRc. MD Anderson Cancer Center rdcu.be/ebcvm Leukemia Journal

Treatment-free remission (TFR) in Ph+ ALL. 🧵 on our recent paper (link below) 👉 Unlike CML, no TFR concept exists in Ph+ ALL. This is more relevant nowadays when increasing numbers of pts are not allo-transplanted in CR1 for Ph+ ALL. Question in clinic- how long should I